ClinicalTrials.gg
CompletedNCT02685826Updated Oct 6, 2023Results posted

A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma

A Phase 1/2 interventional study of Durvalumab and Lenalidomide in Multiple Myeloma, sponsored by Celgene. Completed at 54 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-06.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 249 studies testing lenalidomide in Multiple Myeloma — 29 open to participants now, 70 under way, 14 of them phase 3. Lenalidomide · Multiple Myeloma.

Enrollment
103rd of 249
56 · median 50
Started
2016
with 11 others
Phase 1/2
37 of 249
6 open now
Registered
148th of 249
by date
Lead sponsor
14 of 249
Celgene

Among the 249 studies testing lenalidomide in Multiple Myeloma, this one is the 103rd largest by enrollment, is one of 12 that started in 2016, is one of 37 in phase 1/2, and was the 148th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

29 of the 249 studies testing lenalidomide in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 29 open studies →

About lenalidomide

Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 249 studies testing lenalidomide in Multiple Myeloma, or all of them as a file.
02

Study summary

This is a multicenter, open-label, Phase 1/2 study to determine the recommended dose and regimen of durvalumab in combination with lenalidomide (LEN) with and without dexamethasone (dex) in adults with newly diagnosed multiple myeloma (NDMM).

The study will consist of a dose-finding phase as well as a parallel dose-expansion phase to determine the optimal regimen.

******************************************************************************

The study was placed on full clinical hold by the United States (US) Food and Drug Administration (FDA) on 05 Sep 2017. The decision by the FDA was based on data from non-Celgene-sponsored studies related to risks of anti-programmed cell death 1 (PD-1), pembrolizumab, in combination with immunomodulatory agents. As the result, the study was closed for further enrollment, and all subjects were discontinued from all study treatments (durvalumab, lenalidomide and dexamethasone). All subjects are being followed for second primary malignancies (SPMs), every 6 months for 5 years after the last subject has been enrolled as per protocol. After stopping data collection in the clinical database, any SPM events will continue to be recorded in the subject's source documents, and reported to Celgene Drug Safety.

Read the detailed description

The dose-finding phase will determine recommended dose (RD) for durvalumab in combination with lenalidomide (LEN) with and without dexamethasone (dex) in a 28-day treatment cycle. Three treatment Cohorts (A, B, and C) will be enrolled in parallel:

  • Cohort A: durvalumab + LEN + dex in high risk transplant non-eligible (TNE) newly diagnosed multiple myeloma (NDMM) participants;
  • Cohort B: durvalumab + LEN + dex (dex for up to 12 cycles) in ≥ 65 years old TNE NDMM participants who are not high risk;
  • Cohort C: durvalumab + LEN as maintenance in post-transplant high risk NDMM participants.

Based on experience with durvalumab for other indications, the initial dose of durvalumab will be 1500 mg for each treatment cohort. The dose of durvalumab might be de-escalated to 750 mg level.

The dose of LEN will be 25 mg (adjustable per the creatinine clearance [CrCl] value) on Days 1 to 21 of each 28-day treatment cycle for participants in Cohort A and B. The dose of LEN will be 10 mg on Days 1 to 21 of each 28-day treatment cycle for participants in Cohort C.

The dose of dex will be 40 mg/day (for participants ≤ 75 years old) or 20 mg/day (for participants > 75 years old) on Days 1, 8, 15, and 22 of a 28-day cycle for Cohort A and Cohort B (for up to 12 cycles).

Initially, 6 participants will be enrolled into each cohort and each will receive 1500 mg durvalumab.

The dose-limiting toxicity (DLT) evaluation period will be the first treatment cycle.

  • If ≤ 1 of the 6 initial participants experience a DLT within the first cycle, then the dose expansion phase may be initiated with durvalumab 1500 mg as the recommended dose (RD);
  • If 2 or more of the 6 initial participants experience a DLT within the first cycle, then the maximum tolerated dose (MTD) has been exceeded and de-escalation to durvalumab 750 mg level after review of safety and pharmacokinetic/pharmacodynamic (PK/Pd) of the initial 6 participants by the Dose Review Team (DRT).

Any of the cohorts may be removed from the study based on emerging PK, Pd, efficacy or safety data.

Dose de-escalation will only occur after review of safety (DLT) and possibly PK/Pd data by the Dose Review Team ( DRT).

Note: In the US, two treatment arms (A and B) will be enrolled in parallel. Cohort C will enroll upon completion of at least 4 cycles of follow-up for safety assessment of Cohorts A and B.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Open-label
  • Phase 1/2
  • Durvalumab
  • MEDI4736
  • Lenalidomide (Len)
  • Dexamethasone (dex)
  • Multiple Myeloma
  • Newly-Diagnosed (NDMM)
  • Transplant Non-eligible (TNE)
  • PD-L1
  • Durvalumab (DURVA)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must satisfy the following criteria to be enrolled into the study:

    1. Subject is ≥ 18 years of age at the time of signing the form (ICF)
    2. Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted
    3. Subject is willing and able to adhere to the study visit schedule and other protocol requirements
    4. Subject must have documented diagnosis with previously untreated (for cohort C, the induction and consolidation treatment along with the first stem cell transplantation (ASCT) are allowed), symptomatic multiple myeloma (MM) as defined by the criteria below:

MM diagnostic criteria (all 3 required);

  • Monoclonal protein present in the serum and/or urine
  • Clonal bone marrow plasma cells ≥10% or -proven bony or extramedullary plasmacytoma
  • Any one or more of the following myeloma defining events:

    1. one or more of the following Myeloma-related organ dysfunction (at least one of the following);
  • (C) Calcium elevation (serum calcium >11.5 mg/dl )(>2.65 mmol/L)
  • (R) Renal insufficiency (serum creatinine >2 mg/dl)(177 µmol/L or more) or \< 40 ml/min
  • (A) Anemia ( \<10 g/dL or >2 g/dL below the lower limit of laboratory normal)
  • (B) Bone lesions (lytic or osteopenic) one or more bone lesions on skeletal radiography, computed tomography (CT), or positron emission tomography-computed tomography (PET-CT)

    1. one or more of the following biomarkers of :
  • Clonal bone marrow plasma cell percentage ≥60%
  • Abnormal serum free light-chain ratio ≥100 (involved kappa) or \< 0.01 (involved lambda)
  • >1 focal lesions detected by functional imaging including PET/CT and/or whole body magnetic resonance imaging (MRI)

AND have by protein electrophoresis analyses as defined by the following:

  • Immunoglobulin G (IgG) MM: Serum monoclonal paraprotein (M-protein) level ≥ 1.0 g/dl or urine Mprotein level ≥ 200 mg/24 hours
  • Immunoglobulin A (IgA) MM: Serum M-protein level ≥ 0.5 g/dl or urine M-protein level ≥ 200 mg/24 hours
  • Immunoglobulin M (IgM) MM (IgM M-protein plus lytic bone disease documented by skeletal survey plain films): Serum M-protein level ≥ 1.0 g/dl or urine M-protein level ≥ 200 mg/24 hours
  • Immunoglobulin D (IgD) MM: Serum M-protein level ≥ 0.05 g/dl or urine M-protein level ≥ 200 mg/24 hours
  • Light chain MM: Serum M-protein level ≥ 1.0 g/dl or urine M-protein level ≥ 200 mg/24 hours

    1. (ECOG) performance status of 0, 1, or 2
    1. Females of (FCBP) must:

    a. Have two negative pregnancy tests as verified by the investigator prior to starting study treatment. She must agree to ongoing pregnancy testing during the course of the study, and after end of study treatment. This applies even if the subject practices true abstinence from heterosexual contact.

    b. She must either commit to true abstinence from heterosexual contact (which must be reviewed on a monthly basis and be source documented) or agree to use, and be able to comply with, effective without interruption, 28 days prior to starting study treatment, during the study therapy (including dose interruptions), and for 90 days after discontinuation of study treatment.

    c. Refrain from egg cell and blood donation for 90 days after the final dose of durvalumab.

    1. Male subjects must :

    a. Practice true abstinence (which must be reviewed on a monthly basis) or agree to use a condom during sexual contact with a pregnant female or a FCBP while participating in the study, during dose interruptions and for at least 90 days following study treatment discontinuation, even if he has undergone a successful vasectomy.

    b. Refrain from sperm and blood donation for at least 90 days after the final dose of durvalumab.

    1. For Cohort A subject must be transplant non-eligible (TNE) and meet at least one of the following high risk factors:

    a. Cytogenetic abnormalities finding in malignant myeloma clone with t(4; 14); and / or del(17p); and / or 1q amplification; and / or t(14:16); or

    b. International Staging System (ISS) Stage III; or

    c. Serum lactate dehydrogenase (LDH) > 2* (upper limit of normal).

    1. For Cohort B subject must be ≥ 65 years of age at the time of signing the informed consent form (ICF) and transplant non-eligible (TNE); excluding the subjects who meet the Cohort A criteria.
    1. For Cohort C subject must be after first autologous stem cell transplantation (ASCT) for NDMM and meet the following criteria:
    2. Have a post-transplant response as Partial response (PR) or better at the time of enrollment to this study;
    3. Have one of the following high risk factors at the time of NDMM diagnosis;
  • Cytogenetic abnormalities finding in malignant myeloma clone with t(4; 14); and / or del(17p); and / or 1q amplification; and / or t(14; 16); or
  • ISS stage III; or
  • Serum LDH > 2*ULN;

    c. Minimal residual disease (MRD) positive (defined as more than 1 malignant cell in 105 cells) measured by ClonoSIGHT™NGS assay of a BMA sample) at the time of enrollment to this study; BMA sample collected at the time of multiple myeloma diagnosis, prior to induction therapy available for central MRD assessment by ClonoSIGHT™NGS assay

Exclusion criteria

Exclusion Criteria:

  • The presence of any of the following will exclude a subject from enrollment:

    1. Previous treatment with anti-myeloma therapy (does not include radiotherapy, bisphosphonates, or a single short course of (ie, less than or equal to the equivalent of dexamethasone 40 mg/day for 4 days; such a short course of steroid treatment must not have been given within 14 days of Cycle 1 Day 1), for Cohort C, the induction and consolidation treatment along with the first stem cell transplantation (ASCT) are allowed)
    2. Any of the following laboratory abnormalities:

      1. (ANC) \< 1,000/μL
      2. Untransfused count \< 75,000 cells/μL
      3. Serum /serum glutamic oxaloacetic transaminase (SGOT/AST) or alanine aminotransferase (SGPT/ALT) > 2.5* (ULN)
      4. Serum total > 1.5*ULN or > 3.0 mg/dL for subjects with documented Gilbert's syndrome
      5. Corrected serum calcium >13.5 mg/dL (> 3.4 mmol/L)
    3. Renal failure requiring hemodialysis or peritoneal dialysis
    4. Any serious medical condition that places the subject at an unacceptable risk if he or she participates in this study. Examples of such a medical condition are, but are not limited to, subject with unstable cardiac disease as defined by: cardiac events such as myocardial infarction (MI) within the past 6 months, (New York Heart Association) heart failure class III-IV, uncontrolled atrial fibrillation or hypertension; subjects with conditions requiring chronic steroid or treatment, such as rheumatoid arthritis, multiple sclerosis and lupus, that likely need additional steroid or immunosuppressive treatments in addition to the study treatment
    5. Peripheral neuropathy ≥ Grade 2
    6. Primary AL (immunoglobulin light-chain) amyloidosis and myeloma complicated by amyloidosis
    7. Prior history of , other than MM, unless the subject has been free of the disease for ≥ 5 years with the exception of the following non-invasive malignancies:

      1. Basal cell carcinoma of the skin
      2. Squamous cell carcinoma of the skin
      3. Carcinoma in situ of the cervix
      4. Carcinoma in situ of the breast
      5. Incidental histologic finding of prostate cancer (T1a or T1b using the TNM [tumor, nodes, ] clinical staging system) or prostate cancer that is curative
    8. Subjects is positive for (HIV); chronic or active or active hepatitis A, or C
    9. Subject had prior exposure to immunotherapy, including, but not limited to, other anti- ,anti-PD-1, anti-PD-L1 monoclonal antibody or inhibitor, cell-based therapies, or cancer vaccines
    10. Subjects has history of organ or allogeneic stem cell transplantation
    11. Subjects who have had clinical evidence of central nervous system (CNS) or pulmonary leukostasis, disseminated intravascular coagulation, or CNS multiple myeloma, or plasma cell leukemia
    12. Known or suspected to the contained in the formulation of durvalumab, lenalidomide, or dexamethasone
    13. Major surgery (as defined by the investigator) within the 28 days prior to the first dose of study treatment
    14. Received prior treatment (for any reason)with a monoclonal antibody within 5 half-lives of initiating study treatment
    15. Use of any agents within 28 days or 5 half-lives (whichever is longer) of initiating study treatment
    16. Current or prior use of immunosuppressive medication within 14 days prior to the first dose of study treatment. The following are exceptions to this criterion:

      1. Intranasal, inhaled, topical or local steroid injections (eg, intra-articular injection);
      2. Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or equivalent;
      3. Steroids as premedication for hypersensitivity reactions (eg, computed tomography (CT) scan premedication);
    17. Active or prior documented or inflammatory disorders (including inflammatory bowel disease (eg, colitis, Crohn's disease], diverticulitis with the exception of a prior episode that has resolved or diverticulosis, celiac disease, irritable bowel disease, or other serious gastrointestinal chronic conditions associated with diarrhea; systemic lupus erythematosus; Wegener's syndrome [granulomatosis with polyangiitis); myasthenia gravis; Graves' disease; rheumatoid arthritis; hypophysitis, uveitis) within the past 3 years prior to the start of treatment. The following are exceptions to this criterion:

      1. Subjects with vitiligo or alopecia;
      2. Subjects with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement; or
      3. Subjects with psoriasis not requiring systemic treatment;
    18. History of primary immunodeficiency
    19. Subject has incidence of gastrointestinal disease that may significantly alter the absorption of LEN
    20. Receipt of live, attenuated vaccine within 30 days prior to the first dose of durvalumab
    21. Unable or unwilling to undergo protocol required thromboembolism prophylaxis(for Cohort C, this will be only for the subjects who have a history of VTE)
    22. Females who are pregnant, nursing or breastfeeding, or intend to become pregnant during the participation to the study
    23. Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study
    24. Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study
    25. Any condition that confounds the ability to interpret data from the study
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Cohort A: High risk, TNE

    High risk, transplant non-eligible \[TNE\], newly diagnosed multiple myeloma (NDMM) participants who were administered * Intravenous (IV) durvalumab at 1500 mg on Day 1 of each 28-day cycle * Oral lenalidomide (LEN) 25 mg/day (adjust per the creatinine clearance \[CrCl\]) value on Days 1 to 21 of each 28-day treatment cycle * Oral dexamethasone (dex) 40 mg/day (≤ 75 years old) or 20 mg/day (\> 75 years old) on Days 1, 8, 15, and 22 of each 28-day cycle

    Drug: Durvalumab · Drug: Lenalidomide · Drug: Dexamethasone

  • Experimental
    Cohort B: >=65 years old, TNE

    \>= 65 years old, transplant non-eligible \[TNE\], newly diagnosed multiple myeloma (NDMM) participants who were not high risk were administered * Intravenous (IV) durvalumab at 1500 mg on Day 1 of each 28-day cycle * Oral lenalidomide (LEN) 25 mg/day (adjust per the creatinine clearance \[CrCl\]) value on Days 1 to 21 of each 28-day treatment cycle * Oral dexamethasone (dex) 40 mg/day (≤ 75 years old) or 20 mg/day (\> 75 years old) on Days 1, 8, 15, and 22 of each 28-day cycle, up to 12 cycles

    Drug: Durvalumab · Drug: Lenalidomide · Drug: Dexamethasone

  • Experimental
    Cohort C: High risk, Post-transplant

    High risk, post-transplant NDMM participants were administered the following as maintenance therapy: * Intravenous (IV) durvalumab at 1500 mg on Day 1 of each 28-day cycle * Oral lenalidomide (LEN) 10 mg/day on Days 1 to 21 of each 28-day treatment cycle

    Drug: Durvalumab · Drug: Lenalidomide

Interventions

  • single use vials administered via intravenous infusion

    Also known as: MEDI4736, DUR, DURVA

  • capsules for oral administration

    Also known as: LEN, Revlimid

  • tablets for oral administration

    Also known as: corticosteroid, dex

06

What researchers measure

Primary outcomes

  1. Participants With Dose-Limiting Toxicities (DLTs) During the Dose-Determining Timeframe (Day 1 - Day 28)

    A Dose Review Team (DRT) evaluated DLTs to determine the recommended dose (RD) of Durvalumab to use in the Expansion Period. A DLT was defined as: a. Grade 4 neutropenia for \>= 5 days. b. Grade 3 neutropenia associated with fever (≥ 38.5°C / 101.3°F) of any duration. c. Grade 4 thrombocytopenia or Grade 3 thrombocytopenia with bleeding, or platelets transfusion. d. Grade 4 hematologic toxicity that does not resolve to baseline level \<=72 hours. e. Grade 4 anemia, unexplained by underlying disease. f. Any nonhematologic toxicity Grade ≥ 3 except for alopecia and nausea. g. Treatment interruption \>= 2 weeks due to AE. If ≤ 1 of the 6 initial participants in each cohort experience a DLT during cycle 1, the RD was Durvalumab 1500 mg; If \>=2 of the 6 initial participants in any cohort experience a DLT during cycle 1, the maximum tolerated dose (MTD) was exceeded and the dose level of Durvalumab was de-escalated to 750 mg

    Time frame: First treatment cycle: Day 1 to Day 28

Secondary outcomes

  1. Participants With Treatment Emergent Adverse Events (TEAE)

    An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen during the course of a study. A TEAE includes AEs between the first dose date of either study drug and 90 days after the last dose of study drug. A serious AE is any AE occurring at any dose that: • Results in death; • Is life-threatening; • Requires or prolongs existing inpatient hospitalization; • Results in persistent or significant disability/incapacity; • Is a congenital anomaly/birth defect; • Constitutes an important medical event. The Investigator assessed the relationship of each AE to study drug and graded the severity according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE, Version 4.03): - Grade 1 = Mild - Grade 2 = Moderate (some limitation in activity; no/minimal medical intervention required) - Grade 3 = Severe (limitation in activity; medical intervention required) - Grade 4 = Life-threatening - Grade 5 = Death

    Time frame: Day 1 up to Week 84 (the longer of 90 days after discontinuing treatment with DURVA, or 28 days after the last dose of LEN or dex)

  2. Overall Response Rate (ORR) for Cohorts A and B: Percentage of Participants Who Achieved a Partial Response or Better According to the International Myeloma Working Group (IMWG) Uniform Response Criteria

    Tumor response, including progressive disease, was assessed by the investigators and captured the best assessment of response during the treatment period. ORR was defined as partial response (PR) or better which includes PR, very good partial response (VGPR), complete response (CR), or stringent complete response (sCR). A PR required ≥ 50% reduction of serum M-Protein and reduction in 24-hour urinary M-protein by ≥ 90% or to \< 200 mg per 24 hours. If present at baseline, a ≥ 50% reduction in the size of soft tissue plasmacytomas was also required. sCR required - a negative immunofixation of serum and urine and - disappearance of any soft tissue plasmacytomas and - ≤ 5% plasma cells in bone marrow and normal free light-chain (FLC) ratio and - absence of clonal plasma cells by immunohistochemistry or 2- to 4-color flow cytometry.

    Time frame: Day 1 of each cycle starting with Cycle 2 up to Cycle 17 plus one week for the end of treatment visit (Day 29 up to Week 73)

  3. Response Improvement Rate (RIR) for Cohort C: Percentage of Participants Achieving a Response Improved From Cycle 1 Day 1 as Assessed by the Investigators Using the International Myeloma Working Group (IMWG) Uniform Response Criteria

    Response Improvement Rate is defined as the percentage of participants who achieved a response from treatment as compared to the pre-autologous stem cell transplantation \[ASCT\] diseases measurement used as baseline for response assessment. IMWG response categories could be stable disease (SD), partial response (PR), very good partial response (VGPR), complete response (CR), or stringent complete response (sCR), as long as it represented an improvement compared to prior to transplant.

    Time frame: Baseline (Cycle 1 Day 1); Treatment: Day 1 of each cycle starting with Cycle 2 up to Cycle 15 plus one week for the end of treatment visit (Day 29 up to Week 61)

  4. Time to Response (for Cohorts A and B)

    Time to response (for responders only, per IMWG Uniform Response Criteria) is calculated as the time from the first date of dosing of study medication to the first date of documented response (PR or better).

    Time frame: Day 1 of each cycle starting with Cycle 2 up to Cycle 17 plus one week for the end of treatment visit (Day 29 up to Week 73)

  5. Kaplan-Meier Estimates for Duration of Response (for Cohort A and B)

    Duration of response (for responders only) was defined as the time from earliest date of documented response (PR or better) to the earliest date of disease progression (DP) as determined by the investigator per IMWG Uniform Response criteria or death during study treatment, whichever occurred first.

    Time frame: Day 1 of each cycle starting with Cycle 2 up to Cycle 17 plus one week for the end of treatment visit (Day 29 up to Week 73)

  6. Durvalumab (DURVA) Serum Pharmacokinetic (PK) Parameters in Cycle 1: Area Under the Concentration-time Curve From Time Zero to the Last Measured Time Point (AUC0-last)

    Geometric mean was obtained by computing the arithmetic mean of the logarithm-transformed values of concentration/PK parameters and then using the exponentiation to return the computation to the original scales. Geometric CV% was calculated as follows: CV% = 100\*SQRT(EXP(σ2)-1), where σ2 denotes the variance of the log-transformed values.

    Time frame: pre-infusion (-60 to -5 minutes prior to dose), end of infusion (EOI), 4 hours, 168 hours (Day 8), 336 hours (Day 15) and 504 hours (Day 22) after administration of DURVA on Day 1

  7. Durvalumab (DURVA) Serum PK Parameters in Cycle 1: Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-inf)

    Geometric mean was obtained by computing the arithmetic mean of the logarithm-transformed values of concentration/PK parameters and then using the exponentiation to return the computation to the original scales. Geometric CV% was calculated as follows: CV% = 100\*SQRT(EXP(σ2)-1), where σ2 denotes the variance of the log-transformed values.

    Time frame: pre-infusion (-60 to -5 minutes prior to dose), end of infusion (EOI), 4 hours, 168 hours (Day 8), 336 hours (Day 15) and 504 hours (Day 22) after administration of DURVA on Day 1

  8. Durvalumab (DURVA) Serum PK Parameters in Cycle 1: Maximum Observed Concentration (Cmax)

    Geometric mean was obtained by computing the arithmetic mean of the logarithm-transformed values of concentration/PK parameters and then using the exponentiation to return the computation to the original scales. Geometric CV% was calculated as follows: CV% = 100\*SQRT(EXP(σ2)-1), where σ2 denotes the variance of the log-transformed values.

    Time frame: pre-infusion (-60 to -5 minutes prior to dose), end of infusion (EOI), 4 hours, 168 hours (Day 8), 336 hours (Day 15) and 504 hours (Day 22) after administration of DURVA on Day 1

  9. Durvalumab (DURVA) Serum PK Parameters in Cycle 1: Time to Maximum Observed Concentration (Tmax)

    Time to maximum observed concentration of Durvalumab (DURVA) after multiple doses on day 1 obtained from the observed concentration versus time data

    Time frame: pre-infusion (-60 to -5 minutes prior to dose), end of infusion (EOI), 4 hours, 168 hours (Day 8), 336 hours (Day 15) and 504 hours (Day 22) after administration of DURVA on Day 1

  10. Durvalumab (DURVA) Serum PK Parameters in Cycle 1: Terminal Elimination Half-life (t1/2)

    Geometric mean was obtained by computing the arithmetic mean of the logarithm-transformed values of concentration/PK parameters and then using the exponentiation to return the computation to the original scales. Geometric CV% was calculated as follows: CV% = 100\*SQRT(EXP(σ2)-1), where σ2 denotes the variance of the log-transformed values.

    Time frame: pre-infusion (-60 to -5 minutes prior to dose), end of infusion (EOI), 4 hours, 168 hours (Day 8), 336 hours (Day 15) and 504 hours (Day 22) after administration of DURVA on Day 1

  11. Durvalumab (DURVA) Serum PK Parameters in Cycle 1: Clearance (CL)

    Geometric mean was obtained by computing the arithmetic mean of the logarithm-transformed values of concentration/PK parameters and then using the exponentiation to return the computation to the original scales. Geometric CV% was calculated as follows: CV% = 100\*SQRT(EXP(σ2)-1), where σ2 denotes the variance of the log-transformed values.

    Time frame: pre-infusion (-60 to -5 minutes prior to dose), end of infusion (EOI), 4 hours, 168 hours (Day 8), 336 hours (Day 15) and 504 hours (Day 22) after administration of DURVA on Day 1

  12. Durvalumab (DURVA) Serum PK Parameters in Cycle 1: Volume of Distribution (Vz)

    Geometric mean was obtained by computing the arithmetic mean of the logarithm-transformed values of concentration/PK parameters and then using the exponentiation to return the computation to the original scales. Geometric CV% was calculated as follows: CV% = 100\*SQRT(EXP(σ2)-1), where σ2 denotes the variance of the log-transformed values.

    Time frame: pre-infusion (-60 to -5 minutes prior to dose), end of infusion (EOI), 4 hours, 168 hours (Day 8), 336 hours (Day 15) and 504 hours (Day 22) after administration of DURVA on Day 1

  13. Lenalidomide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 1: Area Under the Concentration-time Curve From Time Zero to the Last Measured Time Point (AUC0-last)

    Geometric mean was obtained by computing the arithmetic mean of the logarithm-transformed values of concentration/PK parameters and then using the exponentiation to return the computation to the original scales. Geometric CV% was calculated as follows: CV% = 100\*SQRT(EXP(σ2)-1), where σ2 denotes the variance of the log-transformed values.

    Time frame: Cycle 1 Day 1: pre-dose, 0.5, 1, 2, 4, and 8 hours post LEN dose

  14. Lenalidomide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 1: Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-inf)

    Geometric mean was obtained by computing the arithmetic mean of the logarithm-transformed values of concentration/PK parameters and then using the exponentiation to return the computation to the original scales. Geometric CV% was calculated as follows: CV% = 100\*SQRT(EXP(σ2)-1), where σ2 denotes the variance of the log-transformed values.

    Time frame: Cycle 1 Day 1: pre-dose, 0.5, 1, 2, 4, and 8 hours post LEN dose

  15. Lenalidomide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 1: Maximum Observed Concentration (Cmax)

    Geometric mean was obtained by computing the arithmetic mean of the logarithm-transformed values of concentration/PK parameters and then using the exponentiation to return the computation to the original scales. Geometric CV% was calculated as follows: CV% = 100\*SQRT(EXP(σ2)-1), where σ2 denotes the variance of the log-transformed values.

    Time frame: Cycle 1 Day 1: pre-dose, 0.5, 1, 2, 4, and 8 hours post LEN dose

  16. Lenalidomide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 1: Time to Maximum Observed Concentration (Tmax)

    Time to maximum observed concentration of Lenalidomide (LEN) after multiple doses on day 1 obtained from the observed concentration versus time data

    Time frame: Cycle 1 Day 1: pre-dose, 0.5, 1, 2, 4, and 8 hours post LEN dose

  17. Lenalidomide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 1: Terminal Elimination Half-life (t1/2)

    Geometric mean was obtained by computing the arithmetic mean of the logarithm-transformed values of concentration/PK parameters and then using the exponentiation to return the computation to the original scales. Geometric CV% was calculated as follows: CV% = 100\*SQRT(EXP(σ2)-1), where σ2 denotes the variance of the log-transformed values.

    Time frame: Cycle 1 Day 1: pre-dose, 0.5, 1, 2, 4, and 8 hours post LEN dose

  18. Lenalidomide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 1: Apparent Clearance (CL/F)

    Geometric mean was obtained by computing the arithmetic mean of the logarithm-transformed values of concentration/PK parameters and then using the exponentiation to return the computation to the original scales. Geometric CV% was calculated as follows: CV% = 100\*SQRT(EXP(σ2)-1), where σ2 denotes the variance of the log-transformed values.

    Time frame: Cycle 1 Day 1: pre-dose, 0.5, 1, 2, 4, and 8 hours post LEN dose

  19. Lenalidomide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 1: Apparent Volume of Distribution (Vz/F)

    Geometric mean was obtained by computing the arithmetic mean of the logarithm-transformed values of concentration/PK parameters and then using the exponentiation to return the computation to the original scales. Geometric CV% was calculated as follows: CV% = 100\*SQRT(EXP(σ2)-1), where σ2 denotes the variance of the log-transformed values.

    Time frame: Cycle 1 Day 1: pre-dose, 0.5, 1, 2, 4, and 8 hours post LEN dose

  20. Lenalidomide (LEN) Plasma PK Parameters in Cycle 1 Day 15: Area Under the Concentration-time Curve From Time Zero to the Last Measured Time Point (AUC0-last)

    Geometric mean was obtained by computing the arithmetic mean of the logarithm-transformed values of concentration/PK parameters and then using the exponentiation to return the computation to the original scales. Geometric CV% was calculated as follows: CV% = 100\*SQRT(EXP(σ2)-1), where σ2 denotes the variance of the log-transformed values.

    Time frame: Cycle 1 Day 15: pre-dose, 0.5, 1, 2, 4, and 8 hours post LEN dose

  21. Lenalidomide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 15: Maximum Observed Concentration (Cmax)

    Geometric mean was obtained by computing the arithmetic mean of the logarithm-transformed values of concentration/PK parameters and then using the exponentiation to return the computation to the original scales. Geometric CV% was calculated as follows: CV% = 100\*SQRT(EXP(σ2)-1), where σ2 denotes the variance of the log-transformed values.

    Time frame: Cycle 1 Day 15: pre-dose, 0.5, 1, 2, 4, and 8 hours post LEN dose

  22. Lenalidomide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 15: Time to Maximum Observed Concentration (Tmax)

    Time to maximum observed concentration of Lenalidomide (LEN) after multiple doses on day 15 obtained from the observed concentration versus time data

    Time frame: Cycle 1 Day 15: pre-dose, 0.5, 1, 2, 4, and 8 hours post LEN dose

  23. Participants Who Developed Anti-drug Antibody Against Durvalumab

    The number of participants who develop antidrug antibody against durvalumab at any of the sampling timepoints during the study.

    Time frame: Pre-dose samples on Day 1 of cycles 1, 2, 4, 6, 10, and 14 (study days 1, 29, 85, 141, 253, 393)

  24. Participants Who Had Either Disease Progression or Death

    This outcome was originally defined as a Kaplan-Meier estimate of progression-free survival (PFS) which estimated the time between first date of dosing of study medication and disease progression, as determined by the investigator using the IMWG Uniform Response Criteria, or death during study treatment, whichever occurred earlier. However due to the early study termination and limited follow-up time, the majority of participants were censored for PFS analysis. Data reported instead represent the number of participants who died during study treatment or had disease progression within 90 days of the last dose of durvalumab.

    Time frame: Day 1 up to Week 84

  25. Participants Who Died Up To Data Cut-off Date (15 December 2017)

    This outcome was originally defined as a Kaplan-Meier estimate of overall survival (OS) and was defined as the time between first date of dosing of study medication and death due to any cause. However due to the early study termination and limited follow-up time, the majority of participants were censored for OS analysis. Data reported instead represent the number of participants who died due to any cause from Day 1 up to data cut-off.

    Time frame: Day 1 up to Week 87

07

Results

Posted Feb 11, 2019
Limitations and caveats
The study was placed on full clinical hold by the United States (US) Food and Drug Administration (FDA) on 05 Sep 2017. As the result, the study was closed for further enrollment, and all participants were discontinued from all study treatments (durvalumab, lenalidomide and dexamethasone). All participants were followed for second primary malignancies (SPMs), every 6 months for 5 years after the last participant has been enrolled as per protocol.

Participant flow

Participant flow — Overall Study
MilestoneCohort A: High Risk, TNECohort B: >=65 Years Old, TNECohort C: High Risk, Post-transplant
Started251021
Completed000
Not completed251021
Withdrew: Adverse event201
Withdrew: Progressive disease210
Withdrew: Withdrawal by subject200
Withdrew: Full clinical hold by fda19920

Outcome measures

PrimaryParticipants With Dose-Limiting Toxicities (DLTs) During the Dose-Determining Timeframe (Day 1 - Day 28)

A Dose Review Team (DRT) evaluated DLTs to determine the recommended dose (RD) of Durvalumab to use in the Expansion Period. A DLT was defined as: a. Grade 4 neutropenia for \>= 5 days. b. Grade 3 neutropenia associated with fever (≥ 38.5°C / 101.3°F) of any duration. c. Grade 4 thrombocytopenia or Grade 3 thrombocytopenia with bleeding, or platelets transfusion. d. Grade 4 hematologic toxicity that does not resolve to baseline level \<=72 hours. e. Grade 4 anemia, unexplained by underlying disease. f. Any nonhematologic toxicity Grade ≥ 3 except for alopecia and nausea. g. Treatment interruption \>= 2 weeks due to AE. If ≤ 1 of the 6 initial participants in each cohort experience a DLT during cycle 1, the RD was Durvalumab 1500 mg; If \>=2 of the 6 initial participants in any cohort experience a DLT during cycle 1, the maximum tolerated dose (MTD) was exceeded and the dose level of Durvalumab was de-escalated to 750 mg

Time frame:
First treatment cycle: Day 1 to Day 28
Reported as:
Count of participants · Participants
Participants With Dose-Limiting Toxicities (DLTs) During the Dose-Determining Timeframe (Day 1 - Day 28)
ParticipantsCohort A: High Risk, TNECohort B: >=65 Years Old, TNECohort C: High Risk, Post-transplant
Participants With Dose-Limiting Toxicities (DLTs) During the Dose-Determining Timeframe (Day 1 - Day 28)110
SecondaryParticipants With Treatment Emergent Adverse Events (TEAE)

An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen during the course of a study. A TEAE includes AEs between the first dose date of either study drug and 90 days after the last dose of study drug. A serious AE is any AE occurring at any dose that: • Results in death; • Is life-threatening; • Requires or prolongs existing inpatient hospitalization; • Results in persistent or significant disability/incapacity; • Is a congenital anomaly/birth defect; • Constitutes an important medical event. The Investigator assessed the relationship of each AE to study drug and graded the severity according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE, Version 4.03): - Grade 1 = Mild - Grade 2 = Moderate (some limitation in activity; no/minimal medical intervention required) - Grade 3 = Severe (limitation in activity; medical intervention required) - Grade 4 = Life-threatening - Grade 5 = Death

Time frame:
Day 1 up to Week 84 (the longer of 90 days after discontinuing treatment with DURVA, or 28 days after the last dose of LEN or dex)
Reported as:
Count of participants · Participants
Participants With Treatment Emergent Adverse Events (TEAE)
ParticipantsCohort A: High Risk, TNECohort B: >=65 Years Old, TNECohort C: High Risk, Post-transplant
>= 1 TEAE24918
>=1 treatment-related TEAE22817
>=1 related to DURVA16415
>=1 related to LEN22815
>=1 related to dex166NA
>=1 TEAE of severity grade 3 or 41987
>=1 severity 3/4, related to study drug1386
>=1 severity 3/4, related to DURVA744
>=1 severity 3/4, related to LEN1184
>=1 severity 3/4, related to dex52NA
>=1 Grade 5 TEAE (Death)101
>=1 Grade 5 TEAE related to study drug001
>=1 Grade 5 TEAE related to DURVA001
>=1 Grade 5 TEAE related to LEN000
>=1 Grade 5 TEAE related to dex00NA
>=1 Serious TEAE1264
>=1 Serious TEAE related to study drug844
>=1 Serious TEAE related to DURVA514
>=1 Serious TEAE related to LEN632
>=1 Serious TEAE related to dex51NA
>=1 TEAE leading to discontinuation of study drug301
>= TEAE leading to discontinuation of DURVA201
>= TEAE leading to discontinuation of LEN300
>= TEAE leading to discontinuation of dex20NA
>=1 leading to delay/reduction/interruption drug1476
>=1 leading to dose delay of DURVA1034
>=1 leading to infusion interruption of DURVA001
>=1 leading to dose reduction of LEN223
>=1 leading to interruption of LEN1355
>=1 leading to dose reduction of dex13NA
>=1 leading to interruption of dex93NA
SecondaryOverall Response Rate (ORR) for Cohorts A and B: Percentage of Participants Who Achieved a Partial Response or Better According to the International Myeloma Working Group (IMWG) Uniform Response Criteria

Tumor response, including progressive disease, was assessed by the investigators and captured the best assessment of response during the treatment period. ORR was defined as partial response (PR) or better which includes PR, very good partial response (VGPR), complete response (CR), or stringent complete response (sCR). A PR required ≥ 50% reduction of serum M-Protein and reduction in 24-hour urinary M-protein by ≥ 90% or to \< 200 mg per 24 hours. If present at baseline, a ≥ 50% reduction in the size of soft tissue plasmacytomas was also required. sCR required - a negative immunofixation of serum and urine and - disappearance of any soft tissue plasmacytomas and - ≤ 5% plasma cells in bone marrow and normal free light-chain (FLC) ratio and - absence of clonal plasma cells by immunohistochemistry or 2- to 4-color flow cytometry.

Time frame:
Day 1 of each cycle starting with Cycle 2 up to Cycle 17 plus one week for the end of treatment visit (Day 29 up to Week 73)
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) for Cohorts A and B: Percentage of Participants Who Achieved a Partial Response or Better According to the International Myeloma Working Group (IMWG) Uniform Response Criteria
percentage of participantsCohort A: High Risk, TNECohort B: >=65 Years Old, TNECohort C: High Risk, Post-transplant
Overall Response Rate (ORR) for Cohorts A and B: Percentage of Participants Who Achieved a Partial Response or Better According to the International Myeloma Working Group (IMWG) Uniform Response Criteria66.7 (51.6 to 79.5)50.0 (26.7 to 73.3)—
SecondaryResponse Improvement Rate (RIR) for Cohort C: Percentage of Participants Achieving a Response Improved From Cycle 1 Day 1 as Assessed by the Investigators Using the International Myeloma Working Group (IMWG) Uniform Response Criteria

Response Improvement Rate is defined as the percentage of participants who achieved a response from treatment as compared to the pre-autologous stem cell transplantation \[ASCT\] diseases measurement used as baseline for response assessment. IMWG response categories could be stable disease (SD), partial response (PR), very good partial response (VGPR), complete response (CR), or stringent complete response (sCR), as long as it represented an improvement compared to prior to transplant.

Time frame:
Baseline (Cycle 1 Day 1); Treatment: Day 1 of each cycle starting with Cycle 2 up to Cycle 15 plus one week for the end of treatment visit (Day 29 up to Week 61)
Reported as:
Number · percentage of participants
Response Improvement Rate (RIR) for Cohort C: Percentage of Participants Achieving a Response Improved From Cycle 1 Day 1 as Assessed by the Investigators Using the International Myeloma Working Group (IMWG) Uniform Response Criteria
percentage of participantsCohort A: High Risk, TNECohort B: >=65 Years Old, TNECohort C: High Risk, Post-transplant
Response Improvement Rate (RIR) for Cohort C: Percentage of Participants Achieving a Response Improved From Cycle 1 Day 1 as Assessed by the Investigators Using the International Myeloma Working Group (IMWG) Uniform Response Criteria——0 (NA to NA)
SecondaryTime to Response (for Cohorts A and B)

Time to response (for responders only, per IMWG Uniform Response Criteria) is calculated as the time from the first date of dosing of study medication to the first date of documented response (PR or better).

Time frame:
Day 1 of each cycle starting with Cycle 2 up to Cycle 17 plus one week for the end of treatment visit (Day 29 up to Week 73)
Reported as:
Median · weeks
Time to Response (for Cohorts A and B)
weeksCohort A: High Risk, TNECohort B: >=65 Years Old, TNECohort C: High Risk, Post-transplant
Time to Response (for Cohorts A and B)4.20 (3.9 to 23.1)4.10 (4.0 to 13.0)—
SecondaryKaplan-Meier Estimates for Duration of Response (for Cohort A and B)

Duration of response (for responders only) was defined as the time from earliest date of documented response (PR or better) to the earliest date of disease progression (DP) as determined by the investigator per IMWG Uniform Response criteria or death during study treatment, whichever occurred first.

Time frame:
Day 1 of each cycle starting with Cycle 2 up to Cycle 17 plus one week for the end of treatment visit (Day 29 up to Week 73)
Reported as:
Median · months
Kaplan-Meier Estimates for Duration of Response (for Cohort A and B)
monthsCohort A: High Risk, TNECohort B: >=65 Years Old, TNECohort C: High Risk, Post-transplant
Kaplan-Meier Estimates for Duration of Response (for Cohort A and B)10.3 (7.2 to NA)NA (NA to NA)—
SecondaryDurvalumab (DURVA) Serum Pharmacokinetic (PK) Parameters in Cycle 1: Area Under the Concentration-time Curve From Time Zero to the Last Measured Time Point (AUC0-last)

Geometric mean was obtained by computing the arithmetic mean of the logarithm-transformed values of concentration/PK parameters and then using the exponentiation to return the computation to the original scales. Geometric CV% was calculated as follows: CV% = 100\*SQRT(EXP(σ2)-1), where σ2 denotes the variance of the log-transformed values.

Time frame:
pre-infusion (-60 to -5 minutes prior to dose), end of infusion (EOI), 4 hours, 168 hours (Day 8), 336 hours (Day 15) and 504 hours (Day 22) after administration of DURVA on Day 1
Reported as:
Geometric mean · day*µg/L
Durvalumab (DURVA) Serum Pharmacokinetic (PK) Parameters in Cycle 1: Area Under the Concentration-time Curve From Time Zero to the Last Measured Time Point (AUC0-last)
day*µg/LCohort A: High Risk, TNECohort B: >=65 Years Old, TNECohort C: High Risk, Post-transplant
Durvalumab (DURVA) Serum Pharmacokinetic (PK) Parameters in Cycle 1: Area Under the Concentration-time Curve From Time Zero to the Last Measured Time Point (AUC0-last)3535033.014 ± 39.83582905.960 ± 21.04026520.655 ± 39.1
SecondaryDurvalumab (DURVA) Serum PK Parameters in Cycle 1: Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-inf)

Geometric mean was obtained by computing the arithmetic mean of the logarithm-transformed values of concentration/PK parameters and then using the exponentiation to return the computation to the original scales. Geometric CV% was calculated as follows: CV% = 100\*SQRT(EXP(σ2)-1), where σ2 denotes the variance of the log-transformed values.

Time frame:
pre-infusion (-60 to -5 minutes prior to dose), end of infusion (EOI), 4 hours, 168 hours (Day 8), 336 hours (Day 15) and 504 hours (Day 22) after administration of DURVA on Day 1
Reported as:
Geometric mean · day*µg/L
Durvalumab (DURVA) Serum PK Parameters in Cycle 1: Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-inf)
day*µg/LCohort A: High Risk, TNECohort B: >=65 Years Old, TNECohort C: High Risk, Post-transplant
Durvalumab (DURVA) Serum PK Parameters in Cycle 1: Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-inf)4944601.671 ± 60.95532568.144 ± 62.56531541.670 ± 36.4
SecondaryDurvalumab (DURVA) Serum PK Parameters in Cycle 1: Maximum Observed Concentration (Cmax)

Geometric mean was obtained by computing the arithmetic mean of the logarithm-transformed values of concentration/PK parameters and then using the exponentiation to return the computation to the original scales. Geometric CV% was calculated as follows: CV% = 100\*SQRT(EXP(σ2)-1), where σ2 denotes the variance of the log-transformed values.

Time frame:
pre-infusion (-60 to -5 minutes prior to dose), end of infusion (EOI), 4 hours, 168 hours (Day 8), 336 hours (Day 15) and 504 hours (Day 22) after administration of DURVA on Day 1
Reported as:
Geometric mean · µg/L
Durvalumab (DURVA) Serum PK Parameters in Cycle 1: Maximum Observed Concentration (Cmax)
µg/LCohort A: High Risk, TNECohort B: >=65 Years Old, TNECohort C: High Risk, Post-transplant
Durvalumab (DURVA) Serum PK Parameters in Cycle 1: Maximum Observed Concentration (Cmax)449280.231 ± 36.7452827.419 ± 25.5482602.748 ± 39.9
SecondaryDurvalumab (DURVA) Serum PK Parameters in Cycle 1: Time to Maximum Observed Concentration (Tmax)

Time to maximum observed concentration of Durvalumab (DURVA) after multiple doses on day 1 obtained from the observed concentration versus time data

Time frame:
pre-infusion (-60 to -5 minutes prior to dose), end of infusion (EOI), 4 hours, 168 hours (Day 8), 336 hours (Day 15) and 504 hours (Day 22) after administration of DURVA on Day 1
Reported as:
Median · day
Durvalumab (DURVA) Serum PK Parameters in Cycle 1: Time to Maximum Observed Concentration (Tmax)
dayCohort A: High Risk, TNECohort B: >=65 Years Old, TNECohort C: High Risk, Post-transplant
Durvalumab (DURVA) Serum PK Parameters in Cycle 1: Time to Maximum Observed Concentration (Tmax)0.051 (0.04 to 0.22)0.106 (0.04 to 0.22)0.180 (0.04 to 0.22)
SecondaryDurvalumab (DURVA) Serum PK Parameters in Cycle 1: Terminal Elimination Half-life (t1/2)

Geometric mean was obtained by computing the arithmetic mean of the logarithm-transformed values of concentration/PK parameters and then using the exponentiation to return the computation to the original scales. Geometric CV% was calculated as follows: CV% = 100\*SQRT(EXP(σ2)-1), where σ2 denotes the variance of the log-transformed values.

Time frame:
pre-infusion (-60 to -5 minutes prior to dose), end of infusion (EOI), 4 hours, 168 hours (Day 8), 336 hours (Day 15) and 504 hours (Day 22) after administration of DURVA on Day 1
Reported as:
Geometric mean · day
Durvalumab (DURVA) Serum PK Parameters in Cycle 1: Terminal Elimination Half-life (t1/2)
dayCohort A: High Risk, TNECohort B: >=65 Years Old, TNECohort C: High Risk, Post-transplant
Durvalumab (DURVA) Serum PK Parameters in Cycle 1: Terminal Elimination Half-life (t1/2)10.984 ± 52.113.376 ± 90.915.844 ± 29.8
SecondaryDurvalumab (DURVA) Serum PK Parameters in Cycle 1: Clearance (CL)

Geometric mean was obtained by computing the arithmetic mean of the logarithm-transformed values of concentration/PK parameters and then using the exponentiation to return the computation to the original scales. Geometric CV% was calculated as follows: CV% = 100\*SQRT(EXP(σ2)-1), where σ2 denotes the variance of the log-transformed values.

Time frame:
pre-infusion (-60 to -5 minutes prior to dose), end of infusion (EOI), 4 hours, 168 hours (Day 8), 336 hours (Day 15) and 504 hours (Day 22) after administration of DURVA on Day 1
Reported as:
Geometric mean · L/day
Durvalumab (DURVA) Serum PK Parameters in Cycle 1: Clearance (CL)
L/dayCohort A: High Risk, TNECohort B: >=65 Years Old, TNECohort C: High Risk, Post-transplant
Durvalumab (DURVA) Serum PK Parameters in Cycle 1: Clearance (CL)0.303 ± 60.90.271 ± 62.50.230 ± 36.4
SecondaryDurvalumab (DURVA) Serum PK Parameters in Cycle 1: Volume of Distribution (Vz)

Geometric mean was obtained by computing the arithmetic mean of the logarithm-transformed values of concentration/PK parameters and then using the exponentiation to return the computation to the original scales. Geometric CV% was calculated as follows: CV% = 100\*SQRT(EXP(σ2)-1), where σ2 denotes the variance of the log-transformed values.

Time frame:
pre-infusion (-60 to -5 minutes prior to dose), end of infusion (EOI), 4 hours, 168 hours (Day 8), 336 hours (Day 15) and 504 hours (Day 22) after administration of DURVA on Day 1
Reported as:
Geometric mean · liters
Durvalumab (DURVA) Serum PK Parameters in Cycle 1: Volume of Distribution (Vz)
litersCohort A: High Risk, TNECohort B: >=65 Years Old, TNECohort C: High Risk, Post-transplant
Durvalumab (DURVA) Serum PK Parameters in Cycle 1: Volume of Distribution (Vz)4.244 ± 33.54.582 ± 33.34.563 ± 42.9
SecondaryLenalidomide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 1: Area Under the Concentration-time Curve From Time Zero to the Last Measured Time Point (AUC0-last)

Geometric mean was obtained by computing the arithmetic mean of the logarithm-transformed values of concentration/PK parameters and then using the exponentiation to return the computation to the original scales. Geometric CV% was calculated as follows: CV% = 100\*SQRT(EXP(σ2)-1), where σ2 denotes the variance of the log-transformed values.

Time frame:
Cycle 1 Day 1: pre-dose, 0.5, 1, 2, 4, and 8 hours post LEN dose
Reported as:
Geometric mean · hour*ng/mL
Lenalidomide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 1: Area Under the Concentration-time Curve From Time Zero to the Last Measured Time Point (AUC0-last)
hour*ng/mLCohort A: High Risk, TNECohort B: >=65 Years Old, TNECohort C: High Risk, Post-transplant
Lenalidomide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 1: Area Under the Concentration-time Curve From Time Zero to the Last Measured Time Point (AUC0-last)1468.102 ± 78.61442.549 ± 29.9591.085 ± 22.3
SecondaryLenalidomide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 1: Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-inf)

Geometric mean was obtained by computing the arithmetic mean of the logarithm-transformed values of concentration/PK parameters and then using the exponentiation to return the computation to the original scales. Geometric CV% was calculated as follows: CV% = 100\*SQRT(EXP(σ2)-1), where σ2 denotes the variance of the log-transformed values.

Time frame:
Cycle 1 Day 1: pre-dose, 0.5, 1, 2, 4, and 8 hours post LEN dose
Reported as:
Geometric mean · hour*ng/mL
Lenalidomide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 1: Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-inf)
hour*ng/mLCohort A: High Risk, TNECohort B: >=65 Years Old, TNECohort C: High Risk, Post-transplant
Lenalidomide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 1: Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-inf)2534.684 ± 48.62011.889 ± 26.8768.104 ± 33.5
SecondaryLenalidomide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 1: Maximum Observed Concentration (Cmax)

Geometric mean was obtained by computing the arithmetic mean of the logarithm-transformed values of concentration/PK parameters and then using the exponentiation to return the computation to the original scales. Geometric CV% was calculated as follows: CV% = 100\*SQRT(EXP(σ2)-1), where σ2 denotes the variance of the log-transformed values.

Time frame:
Cycle 1 Day 1: pre-dose, 0.5, 1, 2, 4, and 8 hours post LEN dose
Reported as:
Geometric mean · ng/mL
Lenalidomide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 1: Maximum Observed Concentration (Cmax)
ng/mLCohort A: High Risk, TNECohort B: >=65 Years Old, TNECohort C: High Risk, Post-transplant
Lenalidomide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 1: Maximum Observed Concentration (Cmax)395.774 ± 56.2354.018 ± 34.7161.372 ± 33.9
SecondaryLenalidomide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 1: Time to Maximum Observed Concentration (Tmax)

Time to maximum observed concentration of Lenalidomide (LEN) after multiple doses on day 1 obtained from the observed concentration versus time data

Time frame:
Cycle 1 Day 1: pre-dose, 0.5, 1, 2, 4, and 8 hours post LEN dose
Reported as:
Median · hour
Lenalidomide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 1: Time to Maximum Observed Concentration (Tmax)
hourCohort A: High Risk, TNECohort B: >=65 Years Old, TNECohort C: High Risk, Post-transplant
Lenalidomide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 1: Time to Maximum Observed Concentration (Tmax)1.050 (0.42 to 4.08)1.925 (0.50 to 4.00)1.150 (0.43 to 4.17)
SecondaryLenalidomide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 1: Terminal Elimination Half-life (t1/2)

Geometric mean was obtained by computing the arithmetic mean of the logarithm-transformed values of concentration/PK parameters and then using the exponentiation to return the computation to the original scales. Geometric CV% was calculated as follows: CV% = 100\*SQRT(EXP(σ2)-1), where σ2 denotes the variance of the log-transformed values.

Time frame:
Cycle 1 Day 1: pre-dose, 0.5, 1, 2, 4, and 8 hours post LEN dose
Reported as:
Geometric mean · hour
Lenalidomide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 1: Terminal Elimination Half-life (t1/2)
hourCohort A: High Risk, TNECohort B: >=65 Years Old, TNECohort C: High Risk, Post-transplant
Lenalidomide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 1: Terminal Elimination Half-life (t1/2)3.477 ± 61.33.051 ± 16.82.883 ± 29.2
SecondaryLenalidomide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 1: Apparent Clearance (CL/F)

Geometric mean was obtained by computing the arithmetic mean of the logarithm-transformed values of concentration/PK parameters and then using the exponentiation to return the computation to the original scales. Geometric CV% was calculated as follows: CV% = 100\*SQRT(EXP(σ2)-1), where σ2 denotes the variance of the log-transformed values.

Time frame:
Cycle 1 Day 1: pre-dose, 0.5, 1, 2, 4, and 8 hours post LEN dose
Reported as:
Geometric mean · L/hour
Lenalidomide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 1: Apparent Clearance (CL/F)
L/hourCohort A: High Risk, TNECohort B: >=65 Years Old, TNECohort C: High Risk, Post-transplant
Lenalidomide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 1: Apparent Clearance (CL/F)8.838 ± 52.712.426 ± 26.813.019 ± 33.5
SecondaryLenalidomide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 1: Apparent Volume of Distribution (Vz/F)

Geometric mean was obtained by computing the arithmetic mean of the logarithm-transformed values of concentration/PK parameters and then using the exponentiation to return the computation to the original scales. Geometric CV% was calculated as follows: CV% = 100\*SQRT(EXP(σ2)-1), where σ2 denotes the variance of the log-transformed values.

Time frame:
Cycle 1 Day 1: pre-dose, 0.5, 1, 2, 4, and 8 hours post LEN dose
Reported as:
Geometric mean · liters
Lenalidomide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 1: Apparent Volume of Distribution (Vz/F)
litersCohort A: High Risk, TNECohort B: >=65 Years Old, TNECohort C: High Risk, Post-transplant
Lenalidomide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 1: Apparent Volume of Distribution (Vz/F)44.329 ± 25.454.689 ± 29.754.157 ± 22.3
SecondaryLenalidomide (LEN) Plasma PK Parameters in Cycle 1 Day 15: Area Under the Concentration-time Curve From Time Zero to the Last Measured Time Point (AUC0-last)

Geometric mean was obtained by computing the arithmetic mean of the logarithm-transformed values of concentration/PK parameters and then using the exponentiation to return the computation to the original scales. Geometric CV% was calculated as follows: CV% = 100\*SQRT(EXP(σ2)-1), where σ2 denotes the variance of the log-transformed values.

Time frame:
Cycle 1 Day 15: pre-dose, 0.5, 1, 2, 4, and 8 hours post LEN dose
Reported as:
Geometric mean · hour*ng/mL
Lenalidomide (LEN) Plasma PK Parameters in Cycle 1 Day 15: Area Under the Concentration-time Curve From Time Zero to the Last Measured Time Point (AUC0-last)
hour*ng/mLCohort A: High Risk, TNECohort B: >=65 Years Old, TNECohort C: High Risk, Post-transplant
Lenalidomide (LEN) Plasma PK Parameters in Cycle 1 Day 15: Area Under the Concentration-time Curve From Time Zero to the Last Measured Time Point (AUC0-last)1911.739 ± 65.51754.349 ± 34.3629.151 ± 16.8
SecondaryLenalidomide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 15: Maximum Observed Concentration (Cmax)

Geometric mean was obtained by computing the arithmetic mean of the logarithm-transformed values of concentration/PK parameters and then using the exponentiation to return the computation to the original scales. Geometric CV% was calculated as follows: CV% = 100\*SQRT(EXP(σ2)-1), where σ2 denotes the variance of the log-transformed values.

Time frame:
Cycle 1 Day 15: pre-dose, 0.5, 1, 2, 4, and 8 hours post LEN dose
Reported as:
Geometric mean · ng/mL
Lenalidomide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 15: Maximum Observed Concentration (Cmax)
ng/mLCohort A: High Risk, TNECohort B: >=65 Years Old, TNECohort C: High Risk, Post-transplant
Lenalidomide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 15: Maximum Observed Concentration (Cmax)409.764 ± 66.0452.850 ± 31.7171.235 ± 33.6
SecondaryLenalidomide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 15: Time to Maximum Observed Concentration (Tmax)

Time to maximum observed concentration of Lenalidomide (LEN) after multiple doses on day 15 obtained from the observed concentration versus time data

Time frame:
Cycle 1 Day 15: pre-dose, 0.5, 1, 2, 4, and 8 hours post LEN dose
Reported as:
Median · hour
Lenalidomide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 15: Time to Maximum Observed Concentration (Tmax)
hourCohort A: High Risk, TNECohort B: >=65 Years Old, TNECohort C: High Risk, Post-transplant
Lenalidomide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 15: Time to Maximum Observed Concentration (Tmax)2.000 (1.00 to 8.00)1.000 (0.55 to 2.00)1.042 (0.47 to 4.00)
SecondaryParticipants Who Developed Anti-drug Antibody Against Durvalumab

The number of participants who develop antidrug antibody against durvalumab at any of the sampling timepoints during the study.

Time frame:
Pre-dose samples on Day 1 of cycles 1, 2, 4, 6, 10, and 14 (study days 1, 29, 85, 141, 253, 393)
Reported as:
Count of participants · Participants
Participants Who Developed Anti-drug Antibody Against Durvalumab
ParticipantsCohort A: High Risk, TNECohort B: >=65 Years Old, TNECohort C: High Risk, Post-transplant
Participants Who Developed Anti-drug Antibody Against Durvalumab010
SecondaryParticipants Who Had Either Disease Progression or Death

This outcome was originally defined as a Kaplan-Meier estimate of progression-free survival (PFS) which estimated the time between first date of dosing of study medication and disease progression, as determined by the investigator using the IMWG Uniform Response Criteria, or death during study treatment, whichever occurred earlier. However due to the early study termination and limited follow-up time, the majority of participants were censored for PFS analysis. Data reported instead represent the number of participants who died during study treatment or had disease progression within 90 days of the last dose of durvalumab.

Time frame:
Day 1 up to Week 84
Reported as:
Count of participants · Participants
Participants Who Had Either Disease Progression or Death
ParticipantsCohort A: High Risk, TNECohort B: >=65 Years Old, TNECohort C: High Risk, Post-transplant
Participants Who Had Either Disease Progression or Death413
SecondaryParticipants Who Died Up To Data Cut-off Date (15 December 2017)

This outcome was originally defined as a Kaplan-Meier estimate of overall survival (OS) and was defined as the time between first date of dosing of study medication and death due to any cause. However due to the early study termination and limited follow-up time, the majority of participants were censored for OS analysis. Data reported instead represent the number of participants who died due to any cause from Day 1 up to data cut-off.

Time frame:
Day 1 up to Week 87
Reported as:
Count of participants · Participants
Participants Who Died Up To Data Cut-off Date (15 December 2017)
ParticipantsCohort A: High Risk, TNECohort B: >=65 Years Old, TNECohort C: High Risk, Post-transplant
Participants Who Died Up To Data Cut-off Date (15 December 2017)201

Adverse events

Collected over SAEs and Other AEs are assessed from first dose up to week 84 (the longer of 90 days after discontinuing treatment with DURVA, or 28 days after the last dose of LEN or DEX). Participants were assessed for all-cause mortality from their first dose to their study completion (Up to approximately 88 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A: High Risk, TNE9/25 (36%)12/25 (48%)24/25 (96%)
Cohort B: >=65 Years Old, TNE3/10 (30%)6/10 (60%)9/10 (90%)
Cohort C: High Risk, Post-transplant5/21 (23.8%)4/21 (19%)18/21 (85.7%)
Most frequent serious events
Showing 10 of 37
Most frequent serious events
EventCohort A: High Risk, TNECohort B: >=65 Years Old, TNECohort C: High Risk, Post-transplant
Adrenal insufficiencyEndocrine disorders0/251/100/21
Inappropriate antidiuretic hormone secretionEndocrine disorders0/251/100/21
DiarrhoeaGastrointestinal disorders1/251/100/21
InfluenzaInfections and infestations1/251/100/21
PneumoniaInfections and infestations0/251/100/21
Muscular weaknessMusculoskeletal and connective tissue disorders0/251/100/21
Transient ischaemic attackNervous system disorders0/251/100/21
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/251/100/21
Febrile neutropeniaBlood and lymphatic system disorders1/250/102/21
PyrexiaGeneral disorders2/250/101/21
Most frequent other events
Showing 10 of 112
Most frequent other events
EventCohort A: High Risk, TNECohort B: >=65 Years Old, TNECohort C: High Risk, Post-transplant
AnaemiaBlood and lymphatic system disorders13/252/103/21
DiarrhoeaGastrointestinal disorders13/252/105/21
NeutropeniaBlood and lymphatic system disorders11/255/103/21
ConstipationGastrointestinal disorders9/254/104/21
PyrexiaGeneral disorders3/254/103/21
InsomniaPsychiatric disorders2/254/103/21
FatigueGeneral disorders4/253/107/21
ThrombocytopeniaBlood and lymphatic system disorders8/252/104/21
Oedema peripheralGeneral disorders8/252/100/21
Decreased appetiteMetabolism and nutrition disorders4/253/102/21

Baseline characteristics

Full analysis population. The Full Analysis Population (FAS) is defined as all participants who are enrolled (signed the inform consent form and meet all eligibility criteria) in the study. Participants are analyzed according to the initial cohort actually assigned.

Age, Continuous
Age, Continuous(years)Cohort A: High Risk, TNECohort B: >=65 Years Old, TNECohort C: High Risk, Post-transplantTotal
Mean75.4 ± 4.1772.5 ± 5.2559.6 ± 7.5268.98 ± 9.33
Age, Customized
Age, Customized(participants)Cohort A: High Risk, TNECohort B: >=65 Years Old, TNECohort C: High Risk, Post-transplantTotal
<=65 years001717
>65 years2510439
<=75 years1272039
>75 years133117
Sex: Female, Male
Sex: Female, Male(Participants)Cohort A: High Risk, TNECohort B: >=65 Years Old, TNECohort C: High Risk, Post-transplantTotal
Female150419
Male10101737
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort A: High Risk, TNECohort B: >=65 Years Old, TNECohort C: High Risk, Post-transplantTotal
American Indian or Alaska Native0000
Asian1102
Native Hawaiian or Other Pacific Islander0000
Black or African American1001
White2191747
More than one race0000
Unknown or Not Reported2046
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)Cohort A: High Risk, TNECohort B: >=65 Years Old, TNECohort C: High Risk, Post-transplantTotal
0 = Fully Active751325
1 = Restrictive but ambulatory145827
2 = ambulatory but unable to work4004
International Staging System (ISS) for MM at Diagnosis
International Staging System (ISS) for MM at Diagnosis(Participants)Cohort A: High Risk, TNECohort B: >=65 Years Old, TNECohort C: High Risk, Post-transplantTotal
Stage I25310
Stage II75719
Stage III1301124
Missing3003
High-Risk Cytogenetic Abnormalities at Baseline
High-Risk Cytogenetic Abnormalities at Baseline(Participants)Cohort A: High Risk, TNECohort B: >=65 Years Old, TNECohort C: High Risk, Post-transplantTotal
Yes170219
No8101937
Minimal Residual Disease (MRD) Status
Minimal Residual Disease (MRD) Status(Participants)Cohort A: High Risk, TNECohort B: >=65 Years Old, TNECohort C: High Risk, Post-transplantTotal
Positive——2121
Negative——00
08

Study locations

54 sites
  • University of Alabama Birmingham
    Birmingham, Alabama 35294-000, United States
  • Winship Cancer Institute of Emory University
    Atlanta, Georgia 30322, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Weill Medical College of Cornell University
    New York, New York 10065, United States
  • Carolinas Healthcare System
    Charleston, South Carolina 28203, United States
  • Swedish Medical Center
    Seattle, Washington 98104, United States
  • Local Institution - 206
    Calgary, Alberta T2N 4N2, Canada
  • Tom Baker Cancer Center
    Calgary, Alberta T2N 4N2, Canada
  • Cross Cancer Institute
    Edmonton, Alberta T6G 1Z2, Canada
  • Local Institution - 203
    Edmonton, Alberta T6G 1Z2, Canada
  • British Columbia Cancer Agency
    Vancouver, British Columbia V5Z 4E6, Canada
  • Local Institution - 202
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Queen Elizabeth II Health Sciences Centre
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Local Institution - 205
    Toronto, Ontario M5G 2M9, Canada
  • Princess Margaret Hospital and University of Toronto
    Toronto, Ontario M5G 2M9, Canada
  • Local Institution - 901
    Copenhagen, 2100, Denmark
  • Rigshospitalet University Hospital
    Copenhagen, 2100, Denmark
  • Local Institution - 903
    Odense, 5000, Denmark
  • Odense Universitetshospital
    Odense, 5000, Denmark
  • Local Institution - 902
    Vejle, 7100, Denmark
  • Vejle Hospital
    Vejle, 7100, Denmark
  • Helsinki UniversityCentral Hospital
    Helsinki, 00029 HUS, Finland
  • Local Institution - 801
    Helsinki, 00029 HUS, Finland
  • Universitatsklinikum Essen
    Essen, 45122, Germany
  • Local Institution - 304
    Koblenz, 56068, Germany
  • Praxis fuer Haematologie und Onkologie Koblenz
    Koblenz, 56068, Germany
  • Local Institution - 302
    Tübingen, 72076, Germany
  • University of Tubingen
    Tübingen, 72076, Germany
  • Local Institution - 404
    Rome, Roma 168, Italy
  • Local Institution - 405
    Bologna, 40138, Italy
  • Policlinico S. Orsola
    Bologna, 40138, Italy
  • I.R.C.C.S. Policlinico San Matteo - Universita di Pavia
    Pavia, 27100, Italy
  • Local Institution - 402
    Pavia, 27100, Italy
  • Local Institution - 403
    Reggio Emilia, 42100, Italy
  • Servizio di Ematologia, A.O. - Arcispedale S.Maria Nuova
    Reggio Emilia, 42100, Italy
  • Policlinico Agostino Gemelli
    Rome, 00168, Italy
  • Azienda Ospedaliera San Giovanni Battista - Ospedale Molinette
    Torino, 10126, Italy
  • Local Institution - 406
    Torino, 10126, Italy
  • Local Institution - 704
    Amsterdam, 1081 HV, Netherlands
  • VU Medical Center
    Amsterdam, 1081 HV, Netherlands
  • Erasmus Medical Center
    Rotterdam, 3015 CN, Netherlands
  • Local Institution - 703
    Rotterdam, 3015 CN, Netherlands
  • Hopsital Germans Trias I Pujol
    Badalona, 08918, Spain
  • Hospital 12 de Octobre
    Madrid, 28041, Spain
  • Local Institution - 505
    Madrid, 28041, Spain
  • Clinica Universitaria de Navarra
    Pamplona, 31008, Spain
  • Local Institution - 501
    Pamplona, 31008, Spain
  • Hospital Universitario de Salamanca
    Salamanca, 37007, Spain
  • Local Institution - 503
    Salamanca, 37007, Spain
  • Hospital Doctor Peset
    Valencia, 46017, Spain
  • Local Institution - 506
    Valencia, 46017, Spain
  • Hospital Universitari i Politecnic La Fe de Valencia
    Valencia, 46026, Spain
  • Local Institution - 504
    Valencia, 46026, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2016 to primary completion in Dec 2017, 19 months.

Results were first posted in Feb 2019, 1 year 1 month after primary completion.

Of 98 industry-sponsored phase 1/2 interventional studies under Multiple Myeloma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 90. This study's 19 months is below that.

Counting every sponsor, half of 201 studies reached it within 65 months; a quarter within 44 and three quarters within 92.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2016
First posted
Feb 19, 2016
StartActual
Apr 25, 2016
Primary completionActual
Dec 15, 2017
CompletionActual
Sep 6, 2022
Results first posted
Feb 11, 2019
Last update
Oct 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02685826
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Feb 19, 2016
Start date
Apr 25, 2016
Primary completion
Dec 15, 2017
Completion
Sep 6, 2022
Results posted
Feb 11, 2019
Last update
Oct 6, 2023

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Durvalumab · Lenalidomide

Start the discussion